xalkori
pfizer europe ma eeig - crizotinib - krabbamein, lungnakrabbamein - Æxlishemjandi lyf - xalkori as monotherapy is indicated for:the first‑line treatment of adults with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with previously treated anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with ros1‑positive advanced non‑small cell lung cancer (nsclc)the treatment of paediatric patients (age ≥6 to.
toviaz
pfizer europe ma eeig - fesóteródín fúmarat - Þvagblöðru, ofvirk - Þvaglát - meðferð einkenna (aukinn tíðni og / eða brýnt þvaglát og / eða bráðatilfinning) sem getur komið fram hjá sjúklingum með ofvirkan þvagblöðruheilkenni.
solifenacin alvogen 5 mg filmuhúðuð tafla (solifenacin portfarma) filmuhúðuð tafla 5 mg
alvogen ehf. - solifenacinum súkkínat - filmuhúðuð tafla - 5 mg
fesoterodine teva forðatafla 4 mg
teva b.v.* - fesoterodinum fúmarat - forðatafla - 4 mg
fesoterodine medical valley forðatafla 8 mg
medical valley invest ab - fesoterodinum fúmarat - forðatafla - 8 mg
dorzolamide alvogen augndropar, lausn 20 mg/ml
alvogen ehf. - dorzolamidum hýdróklóríð - augndropar, lausn - 20 mg/ml
fesoterodine medical valley forðatafla 4 mg
medical valley invest ab - fesoterodinum fúmarat - forðatafla - 4 mg
fesoterodine teva forðatafla 8 mg
teva b.v.* - fesoterodinum fúmarat - forðatafla - 8 mg
solifenacin alvogen 10 mg filmuhúðuð tafla (solifenacin portfarma) filmuhúðuð tafla 10 mg
alvogen ehf. - solifenacinum súkkínat - filmuhúðuð tafla - 10 mg
mydrane stungulyf, lausn 0,2 mg/ml + 3,1 mg/ml + 10 mg/ml
laboratoires thea* - lidocainum hýdróklóríð; phenylephrinum hýdróklóríð; tropicamidum inn - stungulyf, lausn - 0,2 mg/ml + 3,1 mg/ml + 10 mg/ml